Please assess the completion status of the following clinical trial:

Trial Title: Telbivudine in Adults Previously Treated in Idenix-Sponsored Telbivudine Studies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient completed a previous qualifying Idenix-Sponsored trial with telbivudine~* Patient was not discontinued from previous Idenix-Sponsored study~Other protocol-defined inclusion criteria may apply~Exclusion Criteria:~* Patient is pregnant or breastfeeding~* Patient is co-infected with hepatitis C, hepatitis D or HIV~Other protocol-defined exclusion criteria may apply

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- telbivudine (Type: EXPERIMENTAL): telbivudine 600 mg p.o. daily for 104 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).